Soligenix

286 articles with Soligenix

• Soligenix - Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials - April 23, 2019

  4/23/2019

  Soligenix, Inc. issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.

• Soligenix -- Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials

  4/23/2019

  Company provides Q1 2019 update and guidance

• Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer

  4/18/2019

  Enrollment Sufficient to Support the Interim Efficacy Analysis

• Soligenix Receives $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

  4/15/2019

  Soligenix, Inc. announced that it has received approximately $611,000, net of transaction costs, in non-dilutive financing via the state of New Jersey's Technology Business Tax Certificate Transfer Program.

• Soligenix and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for SGX942

  4/9/2019

  Acceptance of Pediatric Investigation Plan is important milestone on the path to submission of Marketing Authorization Application in Europe

• Soligenix Receives US Patent for Dusquetide Related Analogs

  4/4/2019

  Patent broadens protection in infectious disease and oral mucositis, including composition of matter claims

• Soligenix Announces Recent Accomplishments and Year-End 2018 Financial Results

  3/26/2019

  Soligenix, Inc. announced its recent accomplishments and financial results for the year ended December 31, 2018.

• Soligenix Announces Recent Accomplishments And Year-End 2018 Financial Results - March 26, 2019

  3/26/2019

  Soligenix, Inc announced its recent accomplishments and financial results for the year ended December 31, 2018.

• Soligenix to Present at National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC

  3/18/2019

  Soligenix, Inc. announced that they will be presenting at the National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC on March 21, 2019.

• Soligenix to Present at National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC

  3/18/2019

  Soligenix, Inc. announced today that they will be presenting at the National Institutes of Health (NIH) – Commercialization Accelerator Program (CAP) "FeedForward Session" in Washington, DC on March 21, 2019.

• Soligenix to Present at the Boston Oncology Investor Conference 2019

  3/11/2019

  Soligenix, Inc. announced that its Chief Scientific Officer, Oreola Donini, PhD, will deliver a corporate presentation at the Boston Oncology Investor Conference 2019 on Thursday, March 14 at 5:35 PM ET.

• Soligenix Corporate Presentation Webcast Recording

  2/25/2019

  An updated webcast of the Soligenix Corporate Presentation, given by Dr. Christopher J. Schaber, President and CEO, is available on the Company website. To listen and view the presentation, please visit www.soligenix.com.

• Zack's Investment Research, Inc. Research Report Update on Soligenix

  2/12/2019

  Analyst David Bautz, PhD of Zack's Investment Research, Inc. updated coverage on Soligenix, Inc. on February 12, 2019. For more information, please visit SCR.Zacks.com.

• Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®

  2/11/2019

  Soligenix, Inc. announced the allowance of a new United States patent protecting its ricin toxin vaccine, RiVax®.

• Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®

  2/11/2019

  Soligenix, Inc. announced the allowance of a new United States patent protecting its ricin toxin vaccine, RiVax®.

• Soligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine Candidate

  2/7/2019

  Soligenix, Inc. announced publication of a scientific article demonstrating the successful thermostabilization of an Ebola subunit vaccine candidate.

• 

  What's New in the Biodefense Market These Days?

  2/4/2019

  Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.

• Soligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs

  1/23/2019

  Patent broadens protection in infectious disease, including composition of matter claims

• Patent broadens protection in infectious disease, including composition of matter claims

  1/23/2019

  Patent broadens protection in infectious disease, including composition of matter claims   [23-January-2019]   PRINCETON, N.J. , Jan. 23, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical n

• Soligenix to Receive $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

  12/11/2018

  Soligenix, Inc. announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's (NJEDA) New Jersey Technology Business Tax Certificate Transfer program.